Wire · opportunities
FDA approves leniolisib for children aged 4 to 11 with APDS
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 11 September 2026 · Fusion42 review
The FDA approved leniolisib for treating children aged 4 to 11 years with activated PI3Kδ syndrome (APDS), marking the first targeted treatment option addressing the underlying disease pathway for this pediatric group. This expands disease-modifying treatment access beyond previous symptom management and is expected to be available in the US from October 2026.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You have a new chance to target a disease with no prior approved paediatric treatment, shifting focus from symptom management to pathogenesis intervention. Early focus on US paediatric immunology networks could open rapid clinical adoption and patient access.
◆ Coverage
1 source · 11 Sep 2026
◆ Related on Wire
◆ Topics